Email this page: News Release
OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by OncoGenex Pharmaceuticals, Inc. for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps OncoGenex Pharmaceuticals, Inc. prevent automated submissions.